{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:16:25Z","timestamp":1790853385524,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Beta-adrenoceptor agonists ( \u03b2 -agonists), in widespread clinical use for obstructive lung disease, have been associated with an increased risk of cardiovascular mortality. The objective of this study was to assess the association between incident myocardial infarction and the use of inhaled \u03b2 -agonists. We performed a case-control study within the Group Health Cooperative of Puget Sound (GHC). Between 1989 and 1994, we identified 1,444 cases with an incident myocardial infarction and 4,094 control subjects frequency-matched on age, sex, hypertension, and index date. The computerized pharmacy database of the health maintenance organization (HMO) was used to assess the use of \u03b2 -agonists by metered dose inhaler (MDI). Cardiovascular risk factor information was obtained from medical record review. In comparison to subjects who did not fill a \u03b2 -agonist prescription, subjects who had filled one \u03b2 -agonist MDI prescription in the 3 mo prior to their index date had an elevated estimated risk of myocardial infarction (adjusted odds ratio [OR]: 1.67 [95% CI, 1.07 to 2.60]). The elevated risk was limited to those subjects who had a history of cardiovascular disease (adjusted OR: 3.22 [95% CI, 1.63 to 6.35]) and among those with cardiovascular disease, to new users of \u03b2 -agonists (adjusted OR: 7.32 [95% CI, 2.34 to 22.8]). There was no dose\u2013response relationship between \u03b2 -agonists use and risk of myocardial infarction. In this study, new use of \u03b2 -agonists was associated with an increased risk of myocardial infarction, although we cannot determine if the association is causal. Our study suggests that clinicians should exercise caution when giving an initial \u03b2 -adrenoceptor agonist prescription to patients with cardiovascular disease. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled \u03b2 -adrenoceptor agonists.<\/jats:p>","DOI":"10.1164\/ajrccm.161.3.9904006","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T14:14:34Z","timestamp":1365084874000},"page":"827-830","source":"Crossref","is-referenced-by-count":103,"title":["The Risk of Myocardial Infarction Associated with Inhaled \u03b2 -Adrenoceptor Agonists"],"prefix":"10.1093","volume":"161","author":[{"given":"DAVID H.","family":"AU","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine; Cardiovascular Health Research Unit, Department of Medicine; and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROZENN N.","family":"LEMAITRE","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine; Cardiovascular Health Research Unit, Department of Medicine; and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"RANDALL CURTIS","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine; Cardiovascular Health Research Unit, Department of Medicine; and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICHOLAS L.","family":"SMITH","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine; Cardiovascular Health Research Unit, Department of Medicine; and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRUCE M.","family":"PSATY","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine; Cardiovascular Health Research Unit, Department of Medicine; and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,3,1]]},"reference":[{"key":"2026032708371546500_B1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results.","volume":"247","author":"\u03b2-Blocker Heart Attack Trial Research Group","year":"1982","journal-title":"J.A.M.A."},{"key":"2026032708371546500_B2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.","volume":"304","author":"Norwegian Multicenter Study Group","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"2026032708371546500_B3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI109781","article-title":"Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.","volume":"65","author":"Aarons","year":"1980","journal-title":"J. Clin. Invest."},{"key":"2026032708371546500_B4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0006-291X(77)90238-8","article-title":"Elevated \u03b2-adrenergic receptor number after chronic propranolol treatment.","volume":"78","author":"Glaubiger","year":"1977","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026032708371546500_B5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.1990.03440120075040","article-title":"The relative risk of incident coronary heart disease associated with recently stopping the use of \u03b2-blockers.","volume":"263","author":"Psaty","year":"1990","journal-title":"J.A.M.A."},{"key":"2026032708371546500_B6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(89)92505-1","article-title":"Prescribed fenoterol and death from asthma in New Zealand, 1981\u201383: case-control study.","volume":"i","author":"Crane","year":"1989","journal-title":"Lancet"},{"key":"2026032708371546500_B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/thx.46.2.105","article-title":"Prescribed fenoterol and death from asthma in New Zealand, 1981\u20137: a further case-control study.","volume":"46","author":"Grainger","year":"1991","journal-title":"Thorax"},{"key":"2026032708371546500_B8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/thx.45.3.170","article-title":"Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977\u201381.","volume":"45","author":"Pearce","year":"1990","journal-title":"Thorax"},{"key":"2026032708371546500_B9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM199202203260801","article-title":"The use of \u03b2-agonists and the risk of death and near death from asthma.","volume":"326","author":"Spitzer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"2026032708371546500_B10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1164\/ajrccm.154.6.8970341","article-title":"Bronchodilators and acute cardiac death.","volume":"154","author":"Suissa","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032708371546500_B11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archinte.1994.00420120047005","article-title":"The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.","volume":"154","author":"Psaty","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"2026032708371546500_B12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/archinte.1997.00440330066007","article-title":"Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women.","volume":"157","author":"Heckbert","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"2026032708371546500_B13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1995.03530080036038","article-title":"The risk of myocardial infarction associated with antihypertensive drug therapies [see comments].","volume":"274","author":"Psaty","year":"1995","journal-title":"J.A.M.A."},{"key":"2026032708371546500_B14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.101.6.1699","article-title":"Sudden cardiac death in bronchial asthma, and inhaled \u03b2-adrenergic agonists.","volume":"101","author":"Robin","year":"1992","journal-title":"Chest"},{"key":"2026032708371546500_B15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/0140-6736(90)93099-B","article-title":"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.","volume":"336","author":"Wong","year":"1990","journal-title":"Lancet"},{"key":"2026032708371546500_B16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/clpt.1986.146","article-title":"The role of cardiac receptors in the haemodynamic response to a \u03b2-2 agonist.","volume":"40","author":"Strauss","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026032708371546500_B17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1378\/chest.110.3.595","article-title":"Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.","volume":"110","author":"Newhouse","year":"1996","journal-title":"Chest"},{"key":"2026032708371546500_B18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/cs0850651","article-title":"Agonist-induced desensitization of \u03b2-adrenoceptors of bovine bronchial epithelial cells.","volume":"85","author":"Nogami","year":"1993","journal-title":"Clin. Sci."},{"key":"2026032708371546500_B19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-2999(96)00769-8","article-title":"Effect of short and long-acting \u03b22-adrenoceptor agonists on pulmonary \u03b22-adrenoceptor expression in human lung.","volume":"318","author":"Nishikawa","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"2026032708371546500_B20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0922-4106(93)90070-P","article-title":"Differential down-regulation of pulmonary \u03b21- and \u03b22-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline.","volume":"247","author":"Nishikawa","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"2026032708371546500_B21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/clpt.1982.102","article-title":"Extrapulmonary effect of terbutaline during prolonged administration.","volume":"31","author":"Bengtsson","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026032708371546500_B22"},{"key":"2026032708371546500_B23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(97)11084-4","article-title":"Acute respiratory-tract infections and risk of first-time acute myocardial infarction.","volume":"351","author":"Meier","year":"1998","journal-title":"Lancet"},{"key":"2026032708371546500_B24"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/161\/3\/827\/67424474\/ajrccm_161_3_827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/161\/3\/827\/67424474\/ajrccm_161_3_827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:37:27Z","timestamp":1774615047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/161\/3\/827\/8528436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,1]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2000,3,1]]},"published-print":{"date-parts":[[2000,3,1]]}},"URL":"https:\/\/doi.org\/10.1164\/ajrccm.161.3.9904006","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,3]]},"published":{"date-parts":[[2000,3,1]]}}}